1. Please check and comment entries here.
Table of Contents

    Topic review

    NOD2 Gene

    View times: 25
    Submitted by: Lily Guo
    (This entry belongs to Entry Collection "MedlinePlus ")

    Definition

    nucleotide binding oligomerization domain containing 2

    1. Introduction

    The NOD2 gene (previously known as CARD15) provides instructions for making a protein that plays an important role in immune system function. The NOD2 protein is active in some types of immune system cells (including monocytes, macrophages, and dendritic cells), which help protect the body against foreign invaders such as bacteria and viruses. The protein is also active in several types of epithelial cells, including Paneth cells, which are found in the lining of the intestine. These cells help defend the intestinal wall against bacterial infection.

    The NOD2 protein has several critical functions in defending the body against foreign invaders. The protein is involved in recognizing certain bacteria and stimulating the immune system to respond appropriately. When triggered by specific substances produced by bacteria, the NOD2 protein turns on (activates) a protein complex called nuclear factor-kappa-B. This protein complex regulates the activity of multiple genes, including genes that control immune responses and inflammatory reactions. An inflammatory reaction occurs when the immune system sends signaling molecules and white blood cells to a site of injury or disease to fight microbial invaders and facilitate tissue repair.

    The NOD2 protein also appears to play a role in a process called autophagy, which cells use to surround and destroy bacteria, viruses, and other harmful substances. In addition to protecting cells from infection, autophagy is used to recycle worn-out cell parts and break down certain proteins when they are no longer needed. This process is also involved in the self-destruction of cells (apoptosis).

    2. Health Conditions Related to Genetic Changes

    2.1. Crohn disease

    Variations in the NOD2 gene have been associated with an increased risk of Crohn disease, a complex disorder that causes inflammation of the digestive system. In particular, NOD2 gene changes are associated with a form of Crohn disease that affects the lower part of the small intestine (the ileum) and the colon in populations of northern European descent. The three most common NOD2 variations are found in about 40 percent of all people with Crohn disease. The most common of these, written as 3020insC or 1007fs, leads to the production of a NOD2 protein that is slightly shorter than normal. Other common variations change single amino acids in the NOD2 protein. It is unclear how these genetic changes increase the risk of developing Crohn disease. Studies suggest that changes in the NOD2 gene prevent the protein from recognizing bacteria appropriately, allowing these microbes to grow unchecked and invade cells that line the intestine. An abnormal immune response to these bacteria may contribute to inflammation and the digestive problems characteristic of Crohn disease.

    2.2. Blau syndrome

    At least 22 mutations in the NOD2 gene have been found to cause Blau syndrome, an inflammatory disorder that begins in childhood and primarily affects the skin, joints, and eyes. These mutations change single protein building blocks (amino acids) in the NOD2 protein. All of these mutations result in a version of the NOD2 protein that is overactive, which can trigger an abnormal inflammatory reaction and cause swelling and irritation. However, it is unclear how the abnormally active protein causes the specific pattern of inflammation affecting the skin, joints, and eyes that is characteristic of Blau syndrome.

    NOD2 gene mutations can also cause early-onset sarcoidosis, a similar condition that some researchers consider to be a noninherited version of Blau syndrome.

    2.3. Yao syndrome

    Several variations in the NOD2 gene increase the risk of developing Yao syndrome, a disorder that causes episodes of fever and abnormal inflammation affecting many parts of the body. Most people with this condition have a variation in the NOD2 gene written as IVS8+158, which is located in a region of the gene called intron 8. Another relatively common NOD2 gene variation in people with Yao syndrome replaces the amino acid arginine with the amino acid tryptophan at position 702 in the NOD2 protein (written as Arg702Trp or R702W). These variations have also been identified in some people with Crohn disease (described above). About 20 percent of people with Yao syndrome have both the IVS8+158 and R702W variations, and some affected individuals have additional variations in the NOD2 gene.

    The effects of having one, two, or more variations in the NOD2 gene is unclear, although studies suggest that these genetic changes may alter the activity (expression) of the NOD2 gene. It is unknown how these variations might contribute to abnormal inflammation in people with Yao syndrome. Researchers suspect that environmental factors such as infections may also play a role in triggering the disease in people with genetic variants that increase their risk.

    2.4. Other disorders

    Several studies have considered variations in the NOD2 gene as a possible risk factor for a condition called graft-versus-host disease (GVHD). GVHD can occur following certain cancer treatments, such as allogeneic stem cell transplantation. This procedure, which is typically used to treat cancers of the blood and immune system, replaces a patient's diseased blood-forming cells (a type of stem cell) with stem cells from a healthy donor. If the donor's stem cells (the graft) recognize the patient's body (the host) as foreign, they may attack organs and tissues such as the liver, digestive system, and skin. GVHD is the term used to describe this potentially severe reaction.

    A few studies have suggested that variations in the NOD2 gene influence the risk of developing severe complications of GVHD following an allogeneic stem cell transplant. The presence of NOD2 gene variations in both the stem cell donor and the recipient is associated with the greatest risk of a severe reaction. However, other research has found no relationship between NOD2 gene changes and the risk of developing GVHD.

    2.5. Cancers

    A few studies have suggested a possible association between changes in the NOD2 gene, particularly the common variation 3020insC (described above), and the development of several types of cancer. Although some of these studies found an increased risk of cancer in people with a NOD2 gene variation, other research found no such association. It is unclear how changes in this gene might contribute to cancer risk.

    3. Other Names for This Gene

    • ACUG
    • BLAU
    • CARD15
    • caspase recruitment domain family, member 15
    • caspase recruitment domain protein 15
    • CD
    • IBD1
    • inflammatory bowel disease protein 1
    • LRR-containing protein
    • NOD2_HUMAN
    • NOD2B
    • nucleotide-binding oligomerization domain containing 2
    • PSORAS1

    This entry is adapted from https://medlineplus.gov/genetics/gene/nod2

    References

    1. Al Nabhani Z, Dietrich G, Hugot JP, Barreau F. Nod2: The intestinal gatekeeper. PLoS Pathog. 2017 Mar 2;13(3):e1006177. doi:10.1371/journal.ppat.1006177.
    2. Elmaagacli AH, Koldehoff M, Hindahl H, Steckel NK, Trenschel R, Peceny R,Ottinger H, Rath PM, Ross RS, Roggendorf M, Grosse-Wilde H, Beelen DW. Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence therisk for severe acute graft-versus-host disease in patients who underwent anallogeneic transplantation. Transplantation. 2006 Jan 27;81(2):247-54.
    3. Holler E, Rogler G, Herfarth H, Brenmoehl J, Wild PJ, Hahn J, Eissner G,Schölmerich J, Andreesen R. Both donor and recipient NOD2/CARD15 mutationsassociate with transplant-related mortality and GvHD following allogeneic stemcell transplantation. Blood. 2004 Aug 1;104(3):889-94.
    4. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, Almer S,Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R,Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G.Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn'sdisease. Nature. 2001 May 31;411(6837):599-603.
    5. Kanazawa N, Okafuji I, Kambe N, Nishikomori R, Nakata-Hizume M, Nagai S, Fuji A, Yuasa T, Manki A, Sakurai Y, Nakajima M, Kobayashi H, Fujiwara I, Tsutsumi H, Utani A, Nishigori C, Heike T, Nakahata T, Miyachi Y. Early-onset sarcoidosis andCARD15 mutations with constitutive nuclear factor-kappaB activation: commongenetic etiology with Blau syndrome. Blood. 2005 Feb 1;105(3):1195-7.
    6. Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, Häfner R,Chamaillard M, Zouali H, Thomas G, Hugot JP. CARD15 mutations in Blau syndrome.Nat Genet. 2001 Sep;29(1):19-20.
    7. Sidiq T, Yoshihama S, Downs I, Kobayashi KS. Nod2: A Critical Regulator ofIleal Microbiota and Crohn's Disease. Front Immunol. 2016 Sep 20;7:367.
    8. Strober W, Watanabe T. NOD2, an intracellular innate immune sensor involved inhost defense and Crohn's disease. Mucosal Immunol. 2011 Sep;4(5):484-95. doi:10.1038/mi.2011.29.
    9. Wang X, Kuivaniemi H, Bonavita G, Mutkus L, Mau U, Blau E, Inohara N, Nunez G,Tromp G, Williams CJ. CARD15 mutations in familial granulomatosis syndromes: astudy of the original Blau syndrome kindred and other families with large-vessel arteritis and cranial neuropathy. Arthritis Rheum. 2002 Nov;46(11):3041-5.
    10. Yao Q, Shen M, McDonald C, Lacbawan F, Moran R, Shen B. NOD2-associatedautoinflammatory disease: a large cohort study. Rheumatology (Oxford). 2015Oct;54(10):1904-12. doi: 10.1093/rheumatology/kev207.
    11. Yao Q, Zhou L, Cusumano P, Bose N, Piliang M, Jayakar B, Su LC, Shen B. A new category of autoinflammatory disease associated with NOD2 gene mutations.Arthritis Res Ther. 2011;13(5):R148. doi: 10.1186/ar3462.
    12. Yao Q. Nucleotide-binding oligomerization domain containing 2: structure,function, and diseases. Semin Arthritis Rheum. 2013 Aug;43(1):125-30. doi:10.1016/j.semarthrit.2012.12.005.
    More

    Keywords